Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Investor Presentation
Q3 FY25
Investor Presentation
Q3 FY25
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Nectar Lifescience Ltd (NECLIFE) is currently trading at 11.84 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Nectar Lifesciences Ltd is a leading global pharmaceutical company specializing in the manufacturing of Cephalosporin APIs and formulations. It holds a strong market position due to its integrated manufacturing ecosystem, allowing it to excel in advanced pharmaceutical production and distribution capabilities. The company's recent performance highlights a significant increase in PAT by 399.36% YoY in Q3 FY25, driven by operational efficiencies and process improvements. Nectar is actively expanding its contract development and manufacturing organization (CDMO) business, leveraging its extensive manufacturing capabilities to enhance customer relationships and reduce supply chain risks. The company is strategically reducing long-term debt to zero by FY26 through efficient cost management, which is expected to enhance profitability and facilitate self-funded growth initiatives.
Over the past 52 weeks, Nectar Lifescience Ltd has traded between a low of ₹11.21 and a high of ₹29.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Nectar Lifescience Ltd has a market capitalization of approximately 225.93. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Nectar Lifescience Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -0.65 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 225.93 Cr, Nectar Lifescience Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Nectar Lifescience Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Nectar Lifescience Ltd is -0.65. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
74.00 | 305 Cr | 24.18 | 0.94 | 0.00 | 22.69 | 25.33 | 9.70 | |
11.60 | 226 Cr | -0.64 | 0.32 | 0.00 | -18.17 | -14.48 | -19.57 | |
60.59 | 217 Cr | -302.95 | 2.14 | 0.00 | 2.03 | 4.68 | -0.20 | |
47.81 | 208 Cr | 30.45 | 2.19 | 0.00 | 4.78 | 5.68 | 4.50 | |
25.28 | 194 Cr | 18.59 | 1.31 | 0.00 | 10.60 | 10.22 | 4.24 | |
62.60 | 184 Cr | 8.59 | 1.59 | 0.00 | 12.08 | 12.32 | 15.43 | |
156.15 | 162 Cr | -8.27 | 0.72 | 0.00 | -4.87 | -1.11 | -4.56 |
Board Meeting Outcome
Board approved infusion of an inter‑corporate loan of up to INR 120 crore to proposed wholly owned subsidiary Avensis Exports Pvt. Ltd. post‑acquisition; definitive loan terms to be disclosed later; company apologized for delay.
Acquisition & RTA Change
Board approved acquisition of 100% equity of Avensis Exports Pvt Ltd for INR 24,96,000 (80,000 shares at INR 31.20) and change of RTA from KFin to Alankit, with acquisition to complete within ~1 month.
Board Meeting Outcome
Nectar Lifesciences' board approved acquisition of 100% of Avensis Exports Pvt Ltd for Rs.24,96,000 (80,000 shares at Rs.31.20), making it a wholly-owned subsidiary, and approved change of RTA from KFin to Alankit (transition to follow).
Board Meeting Outcome
On March 2, 2026, Nectar Lifesciences' board approved acquiring 100% of Avensis Exports Pvt Ltd for INR 24,96,000 (cash), creating a wholly‑owned real estate subsidiary, and authorised change of RTA from KFin to Alankit (transition to follow).
Postal Ballot Results
Shareholders via remote e‑voting (Jan 30–Feb 28, 2026) approved appointment of Mr. Sushil Kapoor as Director (liable to retire) and as Wholetime Director (Director – Finance) for 3 years, and adoption of amended MoA; scrutinizer: Prince Chadha; results passed with requisite majority on Feb 28, 2026.
Postal Ballot Results
Nectar Lifesciences' postal ballot (remote e‑voting Jan 30–Feb 28, 2026) passed three resolutions: appointment of Mr. Sushil Kapoor as Director and as Whole‑time Director (Finance) for 3 years, and adoption of amended MOA.
Bearish
3
Neutral
4
Bullish
7
Bearish
35
Neutral
4
Bullish
7
Bearish
32
Neutral
0
Bullish
0
Nectar Lifesciences Ltd is a leading global pharmaceutical company specializing in the manufacturing of Cephalosporin APIs and formulations. It holds a strong market position due to its integrated manufacturing ecosystem, allowing it to excel in advanced pharmaceutical production and distribution capabilities.
The company's recent performance highlights a significant increase in PAT by 399.36% YoY in Q3 FY25, driven by operational efficiencies and process improvements.
Nectar is actively expanding its contract development and manufacturing organization (CDMO) business, leveraging its extensive manufacturing capabilities to enhance customer relationships and reduce supply chain risks.
The company is strategically reducing long-term debt to zero by FY26 through efficient cost management, which is expected to enhance profitability and facilitate self-funded growth initiatives.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
226 Cr
Moderate Risk
-0.6
28.4
—
0.3
29.95
11.21
Sales CAGR
Profit CAGR
ROE
ROCE
